Elantas Beck Intrinsic Value
ELANTAS • Chemicals
Current Stock Price
₹8324.45
Primary Intrinsic Value
₹2497.34
Market Cap
₹6660 Cr
-70.0%
Downside
Median Value
₹2497.34
Value Range
₹1665 - ₹4162
Assessment
Trading Above Calculated Value
Safety Margin
-100.0%
ELANTAS Valuation Methods Summary
| Method | Type | Intrinsic Value | Range | Upside/Downside | Details |
|---|---|---|---|---|---|
| P/E Based Valuation | earnings | ₹2497.34 | ₹1997.87 - ₹2996.81 | -70.0% | EPS: ₹186.40, Sector P/E: 12x |
| Book Value Method | asset | ₹1664.89 | ₹1498.40 - ₹1831.38 | -80.0% | Book Value/Share: ₹1083.75, P/B: 1.0x |
| Revenue Multiple Method | revenue | ₹2497.34 | ₹2247.61 - ₹2747.07 | -70.0% | Revenue/Share: ₹1120.00, P/S: 0.8x |
| EBITDA Multiple Method | earnings | ₹3329.78 | ₹2996.80 - ₹3662.76 | -60.0% | EBITDA: ₹220.00Cr, EV/EBITDA: 6x |
| Simple DCF (5Y) | dcf | ₹3329.78 | ₹2663.82 - ₹3995.74 | -60.0% | CF Growth: 5.0%, Discount: 15% |
| PEG Ratio Method | growth | ₹2982.40 | ₹2684.16 - ₹3280.64 | -64.2% | EPS Growth: 20.0%, Fair P/E: 16.0x |
| Growth Adjusted P/E | growth | ₹2497.34 | ₹2247.61 - ₹2747.07 | -70.0% | Revenue Growth: 13.5%, Adj P/E: 8.5x |
| ROE Based Valuation | profitability | ₹4162.23 | ₹3746.01 - ₹4578.45 | -50.0% | ROE: 17.1%, P/E Multiple: 14x |
| Graham Defensive Method | conservative | ₹2497.34 | ₹2247.61 - ₹2747.07 | -70.0% | EPS: ₹186.40, BVPS: ₹1083.75 |
Method Types:
Earnings
Asset
DCF
Growth
Dividend
Conservative
Valuation Comparison Chart
ELANTAS Intrinsic Value Analysis
What is the intrinsic value of ELANTAS?
Based on our comprehensive analysis using 9 different valuation methods, the estimated intrinsic value of Elantas Beck (ELANTAS) is ₹2497.34 (median value). With the current market price of ₹8324.45, this represents a -70.0% variance from our estimated fair value.
The valuation range spans from ₹1664.89 to ₹4162.23, indicating ₹1664.89 - ₹4162.23.
Is ELANTAS undervalued or overvalued?
Based on our multi-method analysis, Elantas Beck (ELANTAS) appears to be trading above calculated value by approximately 70.0%.
Financial Health Analysis
| Financial Metric | Current Value | Industry Benchmark | Assessment | Impact on Valuation |
|---|---|---|---|---|
| Current Ratio | 30.84 | Industry Standard: 2.0+ | Above 2.0 | Measures short-term liquidity capacity |
| Return on Equity | 17.1% | Industry Standard: 15%+ | Above 15% | Measures shareholder return efficiency |
| Operating Margin | 20.0% | Industry Standard: 20%+ | Above 20% | Indicates operational efficiency level |
| Asset Turnover Ratio | 0.88x | Industry Standard: 1.0x+ | Above 0.5x | Measures asset utilization efficiency |
Related Pages for Elantas Beck
Additional stock information and data for ELANTAS
Cash Flow Quality Analysis
| Period | Operating Cash Flow | Free Cash Flow | Cash Flow Quality | Sustainability Score |
|---|---|---|---|---|
| March 2024 | ₹63 Cr | ₹63 Cr | Positive Free Cash Flow | 8/10 |
| March 2023 | ₹133 Cr | ₹67 Cr | Positive Free Cash Flow | 8/10 |
| March 2022 | ₹83 Cr | ₹45 Cr | Positive Free Cash Flow | 8/10 |
| March 2021 | ₹29 Cr | ₹13 Cr | Positive Free Cash Flow | 7/10 |
| March 2020 | ₹79 Cr | ₹45 Cr | Positive Free Cash Flow | 8/10 |